Stroes E, et al. - Given that, evolocumab significantly lowers low-density lipoprotein cholesterol (LDL-C) when dosed 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM) subcutaneously, researchers examined 3,146 patients who received ≥ 1 dose of evolocumab or control in four 12-week phase 3 studies to test the premise that LDL-C changes are comparable among different patient subgroups in a pooled analysis of data from phase 3 trials. Irrespective of demographic and disease characteristics, the evolocumab group showed consistent reductions in LDL-C. They also noted that, across groups treated with each evolocumab dosing regimen or control, the incidences of adverse events were similar.